The aim of this study was to determine the usefulness of selected lncRNAs as diagnostic and prognostic biomarkers in melanoma patients with a BRAF V600 gene mutation and undergoing targeted therapy with BRAF inhibitors in combination with MEK inhibitors. Here, MAP2K7 is linked to melanoma.